Equities Analysts Offer Predictions for LFCR Q1 Earnings

Key Points

• KeyCorp estimates Lifecore Biomedical will report a Q1 2026 earnings per share of ($0.31) and has a "Sector Weight" rating on the stock.
• Other analysts have mixed opinions, with William Blair rating it "outperform" and Wall Street Zen upgrading it to "hold"; currently, the consensus rating is a "Moderate Buy".
• Lifecore Biomedical reported a revenue of $36.44 million for the last quarter but missed the earnings estimate, reflecting challenges in its financial performance.

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) - Stock analysts at KeyCorp issued their Q1 2026 earnings per share (EPS) estimates for shares of Lifecore Biomedical in a report issued on Wednesday, September 3rd. KeyCorp analyst P. Knight forecasts that the company will post earnings per share of ($0.31) for the quarter. KeyCorp has a "Sector Weight" rating on the stock. The consensus estimate for Lifecore Biomedical's current full-year earnings is ($0.91) per share. KeyCorp also issued estimates for Lifecore Biomedical's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.46) EPS.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. The company had revenue of $36.44 million for the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS.

Other analysts also recently issued reports about the company. William Blair assumed coverage on Lifecore Biomedical in a research note on Wednesday, May 21st. They set an "outperform" rating on the stock. Wall Street Zen upgraded Lifecore Biomedical from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Lifecore Biomedical Stock Down 2.3%

LFCR stock traded down $0.17 on Friday, reaching $7.09. 41,573 shares of the company traded hands, compared to its average volume of 209,406. Lifecore Biomedical has a one year low of $4.33 and a one year high of $8.85. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.84 and a quick ratio of 1.77. The company has a market cap of $265.24 million, a P/E ratio of -5.41 and a beta of 0.64. The firm has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $6.95.

Hedge Funds Weigh In On Lifecore Biomedical

A number of institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after buying an additional 1,886 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of Lifecore Biomedical by 2.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock worth $585,000 after buying an additional 1,900 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Lifecore Biomedical by 8.4% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 32,761 shares of the company's stock worth $266,000 after buying an additional 2,528 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after buying an additional 3,012 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Lifecore Biomedical by 3.8% in the 1st quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company's stock worth $589,000 after buying an additional 3,091 shares during the last quarter. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.